title: Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
abstract: OBJECTIVE
  The aim of this study was to evaluate the effect of secondary cytoreductive surgery (SCRS) on survival and to determine prognostic factors that may predict surgical and survival outcome.
  
  
  METHODS
  Between 1999 and 2011, data of 67 patients who had SCRS for epithelial ovarian cancer were evaluated. Factors that had an impact on survival were determined by statistical analysis.
  
  
  RESULTS
  Univariate analysis showed that the number of chemotherapy cycles after primary surgery, CA 125 level at SCRS, number of recurrent tumors, recurrence before SCRS, disease dissemination, and number of chemotherapy cycles after SCRS were significantly associated with disease free survival after SCRS. In multivariate analysis, serum CA125 level, tumor dissemination, and number of chemotherapy cycles after SCRS were significantly associated with disease free survival. Moreover, univariate analysis showed that recurrence before SCRS was significantly associated with overall survival.
  
  
  CONCLUSIONS
  SCRS may be beneficial for first relapsed, localized paclitaxel/platinum sensitive epithelial ovarian tumors and patients with a low serum CA 125 level and those who will receive ≥ 6 chemotherapy cycles after SCRS. This procedure should be considered in selected patient populations.
authors.affiliation: Department of Gynecologic Oncology, Etlik Zübeyde Hanım Women's Health Teaching and Research Hospital, Ankara, Turkey.
authors.forename: Nurettin
authors.initials: N
authors.lastname: Boran
authors.forename: Deniz
authors.initials: D
authors.lastname: Hizli
authors.forename: Saynur
authors.initials: S
authors.lastname: Yilmaz
authors.forename: Taner
authors.initials: T
authors.lastname: Turan
authors.forename: Bülent
authors.initials: B
authors.lastname: Celik
authors.forename: Emine
authors.initials: E
authors.lastname: Karabuk
authors.forename: Zuhal
authors.initials: Z
authors.lastname: Isikdogan
authors.forename: Gökhan
authors.initials: G
authors.lastname: Tulunay
authors.forename: M Faruk
authors.initials: MF
authors.lastname: Kose
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000601:surgery*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D017239:Paclitaxel / Q000008:administration & dosage; D010984:Platinum / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018394:CA-125 Antigen; D010984:Platinum; D017239:Paclitaxel